PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer

Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment

(2018) Samaresh Sau et al.   JOURNAL OF CONTROLLED RELEASE

CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer

(2018) Zhaoxian Wang et al.   Nanomedicine-Nanotechnology Biology and Medicine

Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages

(2018) Hashem O. Alsaab et al.   BIOMATERIALS

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug

(2017) Samaresh Sau et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Cancer: Imaging with antibodies

(2017) Rosie Mestel   NATURE

Beyond the margins: real-time detection of cancer using targeted fluorophores

(2017) Ray R. Zhang et al.   Nature Reviews Clinical Oncology

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy

(2017) Fanny Jean et al.   Therapeutic Advances in Medical Oncology

Antibody drug conjugates: lessons from 20 years of clinical experience

(2016) A. W. Tolcher   ANNALS OF ONCOLOGY

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Green Synthesis and Characterization of Monodispersed Gold Nanoparticles: Toxicity Study, Delivery of Doxorubicin and Its Bio-Distribution in Mouse Model

(2016) Sudip Mukherjee et al.   Journal of Biomedical Nanotechnology

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

(2016) Samit Chatterjee et al.   Oncotarget

Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?

(2016) E. Pure et al.   Cancer Immunology Research

Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer

(2016) Steve Knutson et al.   PLoS One

NF-κB Regulates PD-1 Expression in Macrophages

(2015) Alexander P. R. Bally et al.   JOURNAL OF IMMUNOLOGY

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Cationic lipid-conjugated dexamethasone as a selective antitumor agent

(2014) Samaresh Sau et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012)   ANNALS OF ONCOLOGY

Doxorubicin pathways

(2010) Caroline F. Thorn et al.   Pharmacogenetics and Genomics